Product Images Lisdexamfetamine Dimesylate

This text appears to be a description of a medication called Lisdexamfetamine Dimesylate in capsule form. The medication is available in packages of 20 capsules and 30 capsules. Each capsule contains 20mg of Lisdexamfetamine Dimesylate. The usual dosage and storage instructions are provided. The medication is distributed by American Health Packaging. It is recommended to follow the full prescribing information and use the medication as directed.*

This text appears to be a description of a medication package containing Lisdexamfetamine Dimesylate capsules. The package includes 30 capsules, with each capsule containing 30mg of Lisdexamfetamine Dimesylate. The typical dosage information is stated to be in the full prescribing information. The package is required to be stored between 20°C to 25°C (68°F to 77°F). This product requires a DEA order form and is distributed by American Health Packaging in Columbus, Ohio.*

This text provides details about a medication called Lisdexamfetamine Dimesylate, available in capsule form. The package contains either 20 or 30 capsules. It includes information on the drug content, dosage instructions, storage conditions, and the manufacturer details. The text also mentions the requirement of a DEA Order Form for purchasing this medication. It is recommended to consult the full prescribing information for proper usage guidance.*

This text appears to be product information for capsules containing Lisdexamfetamine Dimesylate, with each bottle containing 30 capsules in a package. The dosage and storage instructions are provided, as well as details about the drug concentration. It also mentions DEA Order Form requirement and advises not to use if the blister is open or broken. The product is distributed by American Health Packaging.*

This information includes details about a medication with the NDC number 60667-940-21, lisdexamfetamine dimesylate capsules. The package contains 30 capsules in a 3 x 10 configuration. The drug is used for treating certain conditions and each capsule contains lisdexamfetamine dimesylate. The recommended storage conditions are between 20-25°C. It indicates that a prescription is required and warns against using if the blister is torn or broken. The product is distributed by American Health Packaging in Columbus, Ohio.*

This text provides information about a medication called Lisdexamfetamine Dimesylate in capsule form. The packaging contains 20 or 30 capsules and lists the active ingredient as Lisdexamfetamine Dimesylate. It includes dosage instructions and storage recommendations. The medication is distributed by American Health Packaging in Columbus, Ohio. Additionally, it mentions DEA Order Form requirement for purchasing.*

This text provides information regarding a study or data analysis related to a special population, primarily focusing on factors such as gender, age groups (65-74 years and 75 years or older), levels of renal impairment (mild, moderate, severe, end-stage renal disease), PK (pharmacokinetics), fold change, and 90% confidence interval. The text also mentions numbers (10, 15, 20, 25) which could be related to specific measurements or results in the study.*

This text appears to be a comparison of changes in Cmax, AUC, and fold change with 90% confidence interval for the drugs Guanfacine, Venlafaxine, and Omeprazole. The data is presented in a table format with time points mentioned at the bottom. The text also references changes relative to a reference point.*

This is a list of drugs that interact with different CYP enzyme substrates and their effects on PK parameters. The drugs include Guanfacine, Venlafaxine, Caffeine, Dextromethorphan, Omeprazole, Midazolam. The text also mentions fold change and confidence intervals in PK parameters. This information can be valuable for understanding potential drug interactions and their impact on metabolism.*

This text provides information on the Kaplan-Meier Estimated Proportion of Patients with Treatment Failure for Pediatric Patients aged 6 to 17 in Study 6. Additionally, it presents the LS Mean (SE) PERMP Total Score by Treatment and Time-point for Adults aged 18 to 55 with ADHD after 1 week of double-blind treatment in Study 8. The text also mentions that a higher score on the PERMP scale indicates less severe symptoms.*

This text provides information about the Kaplan-Meier estimated proportion of subjects with relapse in adults diagnosed with ADHD. It compares the treatment failure percentage for subjects with ADHD in Study 9 who received Placebo versus Lisdexamfetamine dimesylate capsules over a certain period of time post-randomization.*